Alembic gets tentative FDA nod for generic Brilinta tablets
Alembic Pharmaceuticals recently received tentative approval from the Food and Drug Administration for a generic of Astrazeneca’s Briinta (ticagrelor) tablets in a 90-mg dosage strength.
Ticagrelor tablets are indicated to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
The product has a market value of approximately $625 million for the 12 months ended December 2017, according to IQVIA.
Ticagrelor tablets are indicated to reduce the rate of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
The product has a market value of approximately $625 million for the 12 months ended December 2017, according to IQVIA.